These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19151787)

  • 21. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia.
    Kurzrock R; Talpaz M; Estey E; O'Brien S; Estrov Z; Gutterman JU
    Leukemia; 1991 Nov; 5(11):985-90. PubMed ID: 1961041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
    Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
    J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes.
    Musto P; Modoni S; Alicino G; Savino A; Longo A; Bodenizza C; Falcone A; D'Arena G; Scalzulli P; Perla G
    Haematologica; 1994; 79(6):493-9. PubMed ID: 7896207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia.
    Bessho M; Jinnai I; Matsuda A; Saito M; Hirashima K
    Int J Cell Cloning; 1990 Nov; 8(6):445-58. PubMed ID: 2273298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival.
    Crisà E; Foli C; Passera R; Darbesio A; Garvey KB; Boccadoro M; Ferrero D
    Br J Haematol; 2012 Jul; 158(1):99-107. PubMed ID: 22571649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro study of erythropoiesis in patients with aplastic anemia and myelodysplastic syndromes: a possible tool for prospective determination of the clinical effectiveness of growth factors.
    Aoki A; Shibata A
    Hematol Pathol; 1992; 6(3):143-53. PubMed ID: 1429342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.
    Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M
    Br J Haematol; 2009 Feb; 144(3):342-9. PubMed ID: 19036104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol.
    Ganser A; Maurer A; Contzen C; Seipelt G; Ottmann OG; Schadeck-Gressel C; Kolbe K; Haas R; Zander C; Reutzel R; Hoelzer D
    Ann Hematol; 1996 Apr; 72(4):237-44. PubMed ID: 8624378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematopoietic growth factors in the treatment of acquired bone marrow failure states.
    Marsh JC; Ganser A; Stadler M
    Semin Hematol; 2007 Jul; 44(3):138-47. PubMed ID: 17631178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haemopoietic growth factors in myelodysplastic syndromes: towards patient-oriented therapy?
    Clavio M; Balleari E; Garrone A; Ballerini F; Varaldo R; Michelis GL; Balocco M; Abdall N; Colombo N; Grasso R; Gobbi M
    J Exp Clin Cancer Res; 2005 Mar; 24(1):5-16. PubMed ID: 15943026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of recombinant human G-CSF combined with EPO in treatment of patients with MDS].
    Li ZY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):512-3. PubMed ID: 15972155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
    Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
    Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study.
    Vannucchi AM; Bosi A; Linari S; Guidi S; Longo G; Lombardini L; Mariani MP; Saccardi R; Laszlo D; Rossi Ferrini P
    Haematologica; 1997; 82(1):53-6. PubMed ID: 9107083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes.
    Merchav S; Nielsen OJ; Rosenbaum H; Sharon R; Brenner B; Tatarsky I; Scigalla P; Wieczorek L
    Leukemia; 1990 Nov; 4(11):771-4. PubMed ID: 2232891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor.
    Hofmann WK; Ganser A; Seipelt G; Ottmann OG; Zander C; Geissler G; Hoffmann K; Höffken K; Fischer JT; Isele G; Hoelzer D
    Ann Hematol; 1999 Mar; 78(3):125-30. PubMed ID: 10211754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
    Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
    Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
    Marques da Costa R
    Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.
    Stasi R; Brunetti M; Bussa S; Conforti M; Di Giulio C; Crescenzi A; Terzoli E; Vecchione A; Pagano A
    Clin Cancer Res; 1997 May; 3(5):733-9. PubMed ID: 9815743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study.
    Buccisano F; Piccioni AL; Nobile C; Criscuolo M; Niscola P; Tatarelli C; Fianchi L; Villivà N; Neri B; Carmosino I; Gumenyuk S; Mancini S; Voso MT; Maurillo L; Breccia M; Zini G; Venditti A; Fenu S; Spiriti MA; Latagliata R;
    Ann Hematol; 2016 Jun; 95(7):1059-65. PubMed ID: 27091349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.